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Pluripotent stem cell markers can be useful for diagnostic evaluation of human tumors.The novel pluripotent marker stage-specific
embryonic antigen-5 (SSEA-5) is expressed in undifferentiated human induced pluripotent cells (iPSCs), but little is known about
SSEA-5 expression in other primitive tissues (e.g., human tumors). We evaluated SSEA-5 immunoreactivity patterns in human
tumors, cell lines, teratomas, and iPS cells together with another pluripotent cell surfacemarker L1 cell adhesionmolecule (L1CAM).
We tested two hypotheses: (1) SSEA-5 and L1CAM would be immunoreactive and colocalized in human tumors; (2) SSEA-5 and
L1CAMimmunoreactivitywould persist in iPSCs following retinal differentiating treatment. SSEA-5 immunofluorescencewasmost
pronounced in primitive tumors, such as embryonal carcinoma. In tumor cell lines, SSEA-5 was highly immunoreactive in Capan-1
cells, while L1CAM was highly immunoreactive in U87MG cells. SSEA-5 and L1CAM showed colocalization in undifferentiated
iPSCs, with immunopositive iPSCs remaining after 20 days of retinal differentiating treatment. This is the first demonstration of
SSEA-5 immunoreactivity in human tumors and the first indication of SSEA-5 and L1CAM colocalization. SSEA-5 and L1CAM
warrant further investigation as potentially useful tumor markers for histological evaluation or as markers to monitor the presence
of undifferentiated cells in iPSC populations prior to therapeutic use.
1. Introduction
Markers associated with pluripotency and stem cell pheno-
type are often expressed in malignant tissues [1, 2]. These
pluripotent markers can serve as useful diagnostic tools [3, 4]
or as potential targets for cancer stem cell-directed therapies
[5].
Stage-specific embryonic antigen (SSEA) 5 is a novel
cell surface marker of pluripotency [6]. Antibodies against
SSEA-5 can partially immunodeplete teratoma-forming cells
from differentiating iPSC populations [6]. Although SSEA-
5 immunoreactivity has been established for iPSCs [6], it is
unknown whether SSEA-5 is also expressed in humanmalig-
nancies. For comparison with SSEA-5, we chose L1CAM, a
cell surface adhesion molecule involved in self-renewal and
pluripotency of embryonic stem cells [7]. shRNA targeting
of L1CAM expression in glioma cells inhibits tumor growth
in vivo and increases the survival time of tumor-bearing
animals [8]. Since both SSEA-5 and L1CAM are cell surface
markers of pluripotency, they may also be useful together in
monitoring the presence of pluripotent cells in iPSC popu-
lations that undergo differentiation. Therefore, we examined
human tumors, tumor cell lines, teratomas, and iPSCs for
immunoreactivity to SSEA-5 and L1CAM. The goals of this
study were to (1) evaluate immunoreactivity of SSEA-5 in
human tumors, (2) assess potential colocalization of SSEA-5
with another cell surface marker of pluripotency (L1CAM),
and (3) to monitor cell populations for the presence of
residual undifferentiated cells in iPSCs that undergo retinal
differentiation.
2. Materials and Methods
2.1. Cell Culture. The IMR90-4 iPS cell line was maintained
inmTeSR1medium (StemCell Technologies, Vancouver, CA)
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Figure 1: SSEA-5 and L1CAM immunoreactivity in human tumors. Tumor arrays were immunostained for both SSEA-5 (red) and L1CAM
(green) as described in Section 2. For each tumor type, L1CAM, SSEA-5, and a merged image are shown. Note that the primitive tumors
(embryonal carcinoma and neuroectodermal tumor) show predominantly SSEA-5 immunoreactivity (and little L1CAM immunoreactivity),
while retinoblastoma shows more L1CAM immunoreactivity. The urothelial carcinoma showed immunoreactivity for both markers, with
overlap in the merged image. Scale bar = 20 microns.
onMatrigel (BDBiosciences, San Jose, CA) and differentiated
according to published protocols [9]. Retinoblastoma cell line
RB143 was grown in RPMI 1640 (Life Technologies, Grand
Island, NY) with 10% calf serum (HyClone Laboratories,
Inc., Logan, Utah), and prostate carcinoma cell line LNCap
Clone FGC cells were grown in RPMI 1640 with 10% fetal
bovine serum (American Type Culture Collection ATCC,
Manassas, VA). U87-MG and T98G, glioblastoma cell lines,
were maintained in EMEM (ATCC) with 10% fetal bovine
serum.HCT 116, a colorectal carcinoma cell line, andHT-29, a
colon adenocarcinoma cell line, were maintained in McCoy’s
5A medium (ATCC) with 10% fetal bovine serum. Capan-
1 pancreatic adenocarcinoma cells were cultured in Iscove’s
Modified Dulbecco’s medium (ATCC) with 20% fetal bovine
serum. PC-3 prostate adenocarcinoma cells were grown in
F-12K medium (ATCC) with 10% fetal bovine serum. Panc-
1, a pancreatic carcinoma cell line, was grown in DMEM
(ATCC) with 10% fetal bovine serum. Retinoblastoma cell
lines Weri-Rb27 (a generous gift from Dr. John Ludlow) and
Y79 (ATCC) were cultured in DMEM with 10% calf serum.
The cells were maintained in a 37∘C incubator with 5% CO
2
.
MDA-MB-231, a human breast adenocarcinoma cell line,
was grown in Leibovitz’s L15 medium (ATCC) with 10% fetal
bovine serum at 37∘C in 100% room air.
2.2. Microarray of ABCG2+/− RB143 Cells. RB143 human
retinoblastoma cells were magnetically separated using
ABCG2-FITC antibody (Stem Cell Technologies, Vancou-
ver, British Columbia). We chose these two cell popula-
tions (ABCG2+ (stem-like cells) versus ABCG2− cells in
retinoblastoma) based on our previous studies [10–12]. The
resulting ABCG2+ and ABCG2− cells were compared using
a microarray (Agilent Technologies), and a list of genes with
differential expression was generated. L1CAM was selected
from the list for this study based on differential expression,
relevance to stem cell biology and cell surface localization for
comparison with SSEA-5.
2.3. Immunocytochemistry. Cells were rinsed with PBS, spun
onto slides in cytospin solution: 72% isopropanol, 19% ace-
tone, and 7.6% glycerol using a Shandon Cytospin II and
allowed to dry.
For diaminobenzidine immunostaining, the Max Poly
One kit (Syd Labs, Malden, MA) was used. Slides were
blocked for 10 minutes with 3% H
2
O
2
, followed by blocking
with protein block for 10 minutes. Primary antibody diluted
in PBS (or isotype control) was added to the slides and
incubated for 1 hour at room temperature. Primary antibodies
used were L1CAM (Sigma Aldrich, St. Louis, MO) used at
0.25 ug/mL, SSEA-5 (GeneTex, Irvine, CA) used at 10 ug/mL,
and ALDH1A1 (Abcam, Cambridge MA) used at 5.0 ug/mL.
Slides were washed three times with PBS and incubated in
polymerHRP secondary antibody for 15minutes. Afterwash-
ing in PBS, slides were incubated inDAB (diaminobenzidine)
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Figure 2: SSEA-5 and L1CAM immunoreactivity in human tumor cell lines. A variety of human tumor cell lines were immunostained with
either SSEA-5 or L1CAM using diaminobenzidine reaction so that immunopositive cells could be counted in groups of 100. (a) SSEA-5 and
L1CAM immunoreactivity in human tumor cells. L1CAM(yellowbars) are plotted against the left𝑦-axis; SSEA-5 (blue bars) are plotted against
the right 𝑦-axis. Capan-1 displayed the greatest number of SSEA-5+ cells, while U87MG demonstrated the highest numbers of L1CAM+ cells.
For all bars not visible, the number of positive cells was less than 1%. (b) Examples of fluorescent immunoreactivity: HT-29 cells display both
SSEA-5 and L1CAM immunofluorescence, with some colocalization. LNCaP cells have low levels of L1CAM immunofluorescence and no
detectable SSEA-5 immunofluorescence. Microscopic fields of T98G cells are immunonegative for both L1CAM and SSEA-5.
for 5 minutes. Prolong Gold mounting medium (Invitrogen,
Inc., Grand Island, NY) was used to coverslip the slides, and
three groups of 100 cells were counted for positive cells and
graphed using Prism software (Graphpad, La Jolla, CA).
Retinoblastoma, adult, and embryonic tumor tissue
arrayswith corresponding normal tissueswere obtained from
US Biomax, Inc. (Rockville, MD). Prior to immunofluores-
cence staining of teratoma (Applied Stem Cell, Inc, Menlo
Park, CA) and tumor arrays, slides were baked for 60minutes
at 60∘C, treated with xylene and alcohols, boiled in sodium
citrate (pH 6.0), and blocked for one hour at room tempera-
ture in 1% BSA, 0.5% Triton-X100 in PBS. For iPSC cytospin
slides, the xylene, alcohol, and sodium citrate steps were
omitted. Primary antibodies in blocker (or isotype control)
were added to the slides for one hour at room temperature.
Slides were washed three times in PBS and then incubated in
TRITC and/or FITC conjugated secondary antibody (Sigma,
stock concentration listed as ranging from 3–6.5mg/mL),
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Figure 3: SSEA-5, L1CAM, and ALDH1A1 immunoreactivity in iPS-induced teratoma. (a) Paraffin sections of iPS-induced teratomas were
obtained from Stem Cell Technologies and immunostained for both SSEA-5 (red) and L1CAM (green).The same microscopic field is shown.
Note that there are some areas of colocalization for SSEA-5 and L1CAM and areas of only L1CAM immunoreactivity. Scale bar = 15 microns.
(b) Colocalization of SSEA-5 with the stem cell marker ALDH1A1 is shown in iPS-induced teratoma.
diluted 1 : 400 in PBS. Slides were cover-slipped using Prolong
Gold mounting medium containing DAPI (Invitrogen, Inc.)
and photographed using Spot Advanced software.
For DAB staining of tumor cell lines, three groups of 100
cells were counted for immunopositive cells and averaged and
graphed using Prism software. All experiments were repeated
2-3 times for reproducibility.
3. Results
3.1. SSEA-5 and L1CAM Immunoreactivity in Human Tumors.
We evaluated immunoreactivity of SSEA-5 and L1CAM on
a variety of human tumors to determine staining patterns
and potential regions of colocalization. Immunofluorescence
staining with SSEA-5 and L1CAM was carried out on tis-
sue arrays of retinoblastoma, embryonic tumors, and adult
tumors. As shown in Figure 1, SSEA-5 exhibited strong
immunoreactivity in embryonal carcinoma and primitive
neuroectodermal tumors, while L1CAM was much less
intense.There were some areas of colabeling upon immunos-
taining with both SSEA-5 and L1CAM. Retinoblastoma dis-
played predominantly L1CAM staining, with some areas of
SSEA-5 staining. In urothelial carcinoma, both L1CAM and
SSEA-5 were seen, with many regions of colocalization.
3.2. SSEA-5 and L1CAM Immunoreactivity in Human Tumor
Cell Lines. We examined a variety of human tumor cell
lines for SSEA-5 and L1CAM immunoreactivity. DAB-
immunoreactive cells were counted and graphed using Prism
software. L1CAM (yellow bars) are plotted against the left
𝑦-axis; SSEA-5 (blue bars) are plotted against the right 𝑦-
axis. As seen in Figure 2(a), Capan-1, a pancreatic adenocarci-
noma cell line, and HT-29, a colorectal adenocarcinoma cell
line, showed the strongest SSEA-5 staining. Other cell lines
tested were very low to immunonegative for SSEA-5. Capan-
1 displayed the greatest number of SSEA-5+ cells, while
U87MG demonstrated the highest numbers of L1CAM+
cells. For all bars not visible on the graph, the number of
positive cells was less than 1%, as were isotype controls.
In Figure 2(b), examples of immunofluorescent staining are
shown. HT-29 cells demonstrated both SSEA-5 and L1CAM
immunofluorescence with some colocalization. LNCaP cells
have low levels of L1CAM immunofluorescence and no
detectable SSEA-5 immunofluorescence. T98G cells have
very few L1CAM+ cells (less than 1%) and no detectable
SSEA-5.
3.3. SSEA-5 and L1CAM Immunoreactivity in iPS-Induced
Teratoma. Since SSEA-5 is a marker of teratoma-forming
potential for iPSCs [6], we examined iPSC-induced teratomas
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Figure 4: L1CAM and SSEA-5 immunofluorescence persists in differentiating iPSCs. IPSCs prior to differentiation (day 0) and after twenty
days of retinal differentiation (day 20) were immunofluorescently labeled with both SSEA-5 (red) and L1CAM (green). For each condition,
the same microscopic field is shown for L1CAM, SSEA-5, and a merged image. Note the colocalization of SSEA-5 and L1CAM in the
merged images. In addition, dual-labeled SSEA-5 and L1CAM cells remain in the differentiated iPSC population after twenty days of retinal
differentiation. Scale bar = 15 microns.
for SSEA-5 and L1CAM immunoreactivity. Paraffin sections
of teratomas grown in mice from undifferentiated iPSCs
were obtained from Applied StemCell (Menlo Park, CA) and
immunostained for SSEA-5 (red) and L1CAM (green). Since
both SSEA-5 and L1CAM antibodies were specific for human
markers, they bound specifically to human iPSCs that became
part of the teratoma. In Figure 3(a), immunostaining of
teratoma slides with SSEA-5 and L1CAM indicated that both
of these markers were expressed, revealing the presence of
SSEA-5- and L1CAM-expressing pluripotent cells.Therewere
distinct areas of colocalization for SSEA-5 and L1CAMwithin
the teratoma. To further validate the presence of pluripotent
stem cell markers, we chose ALDH1A1, a stem cell marker
[13], for a double labeling experiment with SSEA-5, seen in
Figure 3(b). Colocalization of SSEA-5 and ALDH1A1 was
evident in the teratoma tissue.
3.4. L1CAM and SSEA-5 Immunofluorescence Persists in Dif-
ferentiating iPSCs. Since SSEA-5 is expressed in pluripotent
iPSCs [6], as well as iPSC-induced teratomas (Figure 3),
we investigated the possibility that iPSCs differentiated to a
retinal progenitor cell fate would contain persistent SSEA-
5+ or L1CAM+ cells. Figure 4 illustrates the presence of
both L1CAM and SSEA-5 in iPSCs, with undifferentiated
iPSCs (day 0) exhibiting strong immunofluorescence staining
6 Journal of Biomarkers
and colocalization. After 20 days of differentiation (day 20),
SSEA-5 and L1CAM immunoreactive iPSCs remain, alsowith
extensive colocalization.
4. Discussion
This report represents the first demonstration of SSEA-5
immunoreactivity in human tumors and tumor cell lines and
partial colocalization with the cell surface marker L1CAM.
4.1. SSEA-5 and L1CAM in Human Tumor Samples. SSEA-
5 immunoreactivity in embryonic and neuroectodermal
tumors is consistent with the pluripotent nature of the
marker. Although therewas some colocalizationwith L1CAM
in human tumors, there were distinct areas of SSEA-5
immunoreactivity alone. The regions of single versus double
staining for SSEA-5 and L1CAM require further analysis
to determine other important regional differences within
these tumors. We find biological variation in the percentage
of positive cells for most markers in a variety of tumors
and cell lines. The percentage of positive cells may depend
on the source of the tumor (different patient samples),
regional variation within a particular tumor, primitive versus
differentiated state of the tumor, and so forth. So we are very
careful not to overgeneralize the presence of a marker in all
tumors of a particular type. Since these samples contained
all tumor cells, it was not possible to identify specific tissue
cell types as being immunoreactive. Additional studies are
necessary with a large repository of tumors in order to
determine whether SSEA-5 and/or L1CAMmay be useful for
diagnostic histopathology in a clinical setting.
4.2. SSEA-5 and L1CAM inHuman Tumor Cell Lines. SSEA-5
and L1CAM displayed immunoreactivity in different subsets
of tumor cell lines. The heterogeneity of these cell lines is not
surprising, considering that in our previous studies, ABCG2
was expressed in 4% of retinoblastoma cell lines [10–12].
Capan-1 andHT-29, both originating fromadenocarcinomas,
were the only two cell lines in our study to exhibit sig-
nificant SSEA-5 immunoreactivity. Interestingly, Capan-1, a
pancreatic adenocarcinoma cell line, had a high percentage of
SSEA-5+ cells, while Panc-1 (a pancreatic carcinoma cell line)
was immunonegative for SSEA-5. At the same time, Panc-1,
LNCaP, WERI-RB27, Y79, and U87MG cell lines contained
L1CAM immunoreactive cells, yet none of these cell lines
displayed high levels of SSEA-5 immunoreactivity. This list
of cell lines is not exhaustive and further investigation into
the presence these markers in a variety of tumor cell types
is warranted to determine the significance of SSEA-5 and
L1CAM expression. Once a sequence is established for SSEA-
5, PCR primers can be designed for further analysis.
4.3. SSEA-5 and L1CAM in Teratomas and iPSCs. Stem cells
have considerable therapeutic potential, especially with the
advent of induced pluripotent stem cells (iPSCs) [14]. The
potential of iPSCs as therapeutic agents for disease treatment
is great but comes with the risk of uncontrolled growth of
residual pluripotent cells [15]. iPSCs share common pathways
with oncogenic foci [16], and there are recent reports ofmuta-
tions and epigenetic changes in iPSCs that warrant further
investigation [17, 18]. In this study, we demonstrated SSEA-
5 and L1CAM immunoreactivity with areas of colocalization
in iPSC-induced teratomas, as well as iPSCs before and after
20 days of differentiation to a retinal progenitor cell fate.
Our results indicate that residual L1CAM+ and SSEA-5+
cells remain in iPSCs after 20 days of differentiation. These
results confirm the importance and point to a potentialmeans
of evaluating the persistence of undifferentiated iPSCs cells
following differentiation protocols.
Future studies will reveal the utility of SSEA-5 and
L1CAM in diagnostic and therapeutic strategies in both
cancer biology and regenerative medicine.
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